ReviewFrontiers in immunology2022
Dengue Infection - Recent Advances in Disease Pathogenesis in the Era of COVID-19.
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Frequency of pleural effusion in dengue patients by severity, age and imaging modality: a systematic review and meta-analysis.BMC infectious diseases · 2023Pooled it
- Dengue severity and profiles of complement activation and immune mediators: A multicenter cohort study in Indonesia.PloS one · 2026Article
- Sequential Dengue Virus Infection in Marmosets: Histopathological and Immune Responses in the Liver.Viruses · 2025Article
- Role of biomarkers in predicting disease severity in acute dengue and SARs-CoV-2-Infected patients.BMC infectious diseases · 2025Article
- Dengue and Flavivirus Co-Infections: Challenges in Diagnosis, Treatment, and Disease Management.International journal of molecular sciences · 2025Review
- Advances in Nanobiosensors for Rapid and Sensitive Detection of Dengue Virus Biomarkers by Using Clinical Laboratory.Journal of clinical laboratory analysis · 2025Review
- Utility of VIDASTropical medicine and infectious disease · 2025Article
- Severe Hemolytic Crisis in Uncontrolled AIHA Triggered by Dengue.Case reports in medicine · 2025Article
- Recommendations for dengue vaccine implementation in the elderly population.Therapeutic advances in vaccines and immunotherapy · 2025Review
- Article
- Efficacy of human interleukin-11 analogs for treating dengue fever-associated thrombocytopenia: a prospective cohort.European journal of medical research · 2024Article
- Review
- Serosurveillance of dengue infection and correlation with mosquito pools for dengue virus positivity during the COVID-19 pandemic in Tamil Nadu, India - A state-wide cross-sectional cluster randomized community-based study.medRxiv : the preprint server for health sciences · 2024Article
- Review
- Dengue virus pathogenesis and host molecular machineries.Journal of biomedical science · 2024Review
- Severe dengue infection unmasking drug-induced liver injury: Successful management with N-acetylcysteine.Clinical case reports · 2024Article
- Attrition in serum anti-DENV antibodies correlates with high anti-SARS-CoV-2 IgG levels and low DENV positivity in mosquito vectors-Findings from a state-wide cluster-randomized community-based study in Tamil Nadu, India.PLOS global public health · 2024Article
- USP18 enhances dengue virus replication by regulating mitochondrial DNA release.Scientific reports · 2023Article
- Article
- A short communication of 2022 dengue outbreak in Bangladesh: a continuous public health threat.Annals of medicine and surgery (2012) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 4 countries.
Funding
Abstract
The dynamics of host-virus interactions, and impairment of the host's immune surveillance by dengue virus (DENV) serotypes largely remain ambiguous. Several experimental and preclinical studies have demonstrated how the virus brings about severe disease by activating immune cells and other key elements of the inflammatory cascade. Plasmablasts are activated during primary and secondary infections, and play a determinative role in severe dengue. The cross-reactivity of DENV immune responses with other flaviviruses can have implications both for cross-protection and severity of disease. The consequences of a cross-reactivity between DENV and anti-SARS-CoV-2 responses are highly relevant in endemic areas. Here, we review the latest progress in the understanding of dengue immunopathogenesis and provide suggestions to the development of target strategies against dengue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.